In September 2026, Pacific Life Re announced the appointment of Mei Sum Chan as Head of Medical Analytics, succeeding Ian Collins on his retirement. The 25 September report says Collins had built and led the function and that Chan had most recently advised research and development and global divisions on health and statistics. The reinsurer describes the team’s purpose as understanding emerging health and mortality trends, supporting assumption development and delivering data-driven insight to its business and clients. It did not announce a new insurance product, revised mortality basis or measured claims improvement.
Chan’s experience across actuarial, statistical and epidemiological work makes the appointment relevant beyond a personnel notice. Life and health reinsurers price promises that may extend across many years and populations. The quality of a medical assumption depends on the clinical evidence, the credibility of the insured data and the judgment used to translate research into a portfolio forecast. A leadership change can sharpen these processes; whether it does so will have to be demonstrated over time.
From health trend to actuarial assumption
A new medical observation is not automatically a portfolio-wide change. Incidence, diagnosis rates, treatment patterns, survival and return-to-work outcomes may evolve at different speeds. Employer-sponsored life and disability business also differs from individual protection because of age mix, job exposure, enrolment rules, geography and benefit design. Analysts must decide which evidence is relevant to a particular contract, how much weight to give it and when to revise an assumption. They need to record uncertainty alongside the central estimate.
The practical workflow links epidemiology to exposure data, claims coding, actuarial modelling and underwriting. A credible challenge asks whether reported claims changes reflect true health trends or altered reporting, selection, inflation, benefit definitions or administration. A medical analytics function should test each plausible explanation before recommending a pricing or reserving change. The review cadence also matters: infrequent updates can lag a persistent trend, while reacting to noise can destabilise prices and obscure the underlying signal.
Why group benefits clients should pay attention
Multinational employers and their advisers buy group life, disability and sometimes medical protection from insurers whose risk is partly reinsured. Changes in the reinsurer’s assumptions can flow into insurer pricing, capacity, contract wording or claims support, although no such change was announced in this case. A client should ask its insurer which experience data drive a renewal and whether the effect of medical trend is separately visible from salary growth, headcount, geography and benefit changes.
Where a benefits captive retains part of the risk, the same questions move inside its risk committee. Directors should examine whether internal claims development and external medical evidence point in the same direction, whether extreme outcomes are protected, and whether the assumed trends are reflected consistently in premiums, reserves and reinsurance. Independent challenge should be recorded rather than inferred from the presence of a technical report. A board does not need to become an epidemiology team, but it does need to know which assumptions could move its solvency and liquidity.
Share this:
- More [2]
